Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer AG on Wednesday will urge a U.S. judge to give preliminary approval to a controversial $2 billion settlement that would create a framework to resolve future claims that its top-selling Roundup weedkiller causes cancer.

Bayer seeks approval of $2 billion plan to limit Roundup claims

Bayer (BAYRY) enters a strategic deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for addressing eye diseases.

Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases

MONHEIM, Germany--(BUSINESS WIRE)--Bayer today announced that Brett Begemann, Chief Operating Officer, Crop Science, will retire from his role after 38 years with the company. Rodrigo Santos, currently Head of Crop Science Commercial Operations, Latin America, will succeed Begemann and assume global responsibility for the division's commercial organization, reporting to Liam Condon, President Crop Science and Board of Management Member at Bayer AG. Santos' replacement as Head of Commercial Oper

Bayer Announces New Commercial Leaders for Crop Science Division to Accelerate Growth and Drive Business Transformation

Werner Enterprises

Bayer Aktiengesellschaft (BAYZF) CEO Werner Baumann on Q1 2021 Results - Earnings Call Transcript

Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.

Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Bayer's presence at the meeting underscores the company's commitment to ongoing research that maximizes the utility of existing treatments and development of new therapies to broaden the impact for oncology patients in need. Updated long-term efficacy and safety findings of Vitrakvi® (larotrectinib) for patients w

Bayer Presents Latest Data and New Research to Advance Cancer Care within Oncology Portfolio at 2021 ASCO Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Phase III cardiovascular outcomes study FIGARO-DKD, evaluating the efficacy and safety of the investigational drug finerenone versus placebo when added to standard of care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has met its primary endpoint. The study showed finerenone significantly reduced the composite risk of time to first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or

Bayer's Finerenone Meets Primary Endpoint in Phase III FIGARO-DKD Cardiovascular Outcomes Study in Patients With Chronic Kidney Disease and Type 2 Diabetes

Novartis

A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.

Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources

Biogen

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Lockheed Martin

Merck

Philip Morris

Roche Holding AG

Sanofi

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). e are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The May 2021 Heat Map

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, Bayer announced that two of its top Pharmaceutical executives will take on new leadership roles within the division to advance its position in key therapeutic areas. Nelson Ambrogio, formerly the Senior Vice President, General Manager of Women's Healthcare has been appointed to the role of Senior Vice President, General Manager of Oncology. John Berrios, formerly Vice President of Commercial Operations, will become the Senior Vice President, General Manag

Bayer Pharmaceuticals Taps Two Leaders for New Roles in the U.S.

ST. LOUIS--(BUSINESS WIRE)--Building on the success of the Bayer Carbon Program launched last summer, the company announced today enhancements to the program, providing new opportunities for U.S. growers to participate for the 2021-22 program season. Highlights include a significant geographic expansion, nearly doubling the number of states where growers are eligible to participate. For the first time, growers who have previously adopted some climate-smart farming practices also may be able to

Enhanced Bayer Carbon Program Offers Growers New Opportunities in 2021 and Beyond

Nestle SA

Volkswagen AG

OTC Markets Group Inc.

Ordinarily, OTC stocks to buy are speculative at best, but these firms are well-known entities that happen to have “poor” neighbors. The post 7 OTC Stocks to Buy That Would Easily Qualify for a Major Listing appeared first on InvestorPlace.

7 OTC Stocks to Buy That Would Easily Qualify for a Major Listing

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on the Phase III randomized, double-blind, placebo-controlled clinical study of the investigational use of Aliqopa® (copanlisib) in combination with rituximab given intravenously in

Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a reorganization of its U.S. Corporate Affairs team which will separate Communications and Public Affairs responsibilities. The U.S. Communications function will include current divisional and corporate teams, and the U.S. Public Affairs function will include current U.S. Government Relations and Policy teams, along with U.S. Corporate Engagement. The move aligns with the priorities and anticipated growth trajectories of the global life sci

Bayer Announces Restructuring of U.S. Corporate Affairs To Support Business Priorities, Accelerated Growth Plans

German chemicals group Bayer is preparing to kick off the sale of pest control unit Bayer Environmental Science (BES) this summer with a price tag potentially topping 2 billion euros ($2.4 billion), people close to the matter said.

Bayer to kick off sale of $2.4 billion pest control unit this summer - sources

Amgen

Cardinal Health

CVS Health

Gilead Sciences

General Mills

Henkel AG & Co KGaA

Novo Nordisk

Reckitt Benckiser Group PLC

Walgreens

In the following article, I present 10 recession-proof stocks that are undervalued right now. Including companies from the healthcare sector like Gilead Sciences, Amgen, Novo Nordisk, Walgreens Boots Alliance, CVS Health, Cardinal Health and Bayer.

Hunting For Recession-Proof Bargains: 10 Picks As Prey

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which intermediate-risk adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) transitioned to Adempas® (riociguat) after an insufficient response to phosphodiesterase-5 inhibitor (PDE5i) therapy. Specifically, 41 percent (45/111) of patients receiving

Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

Bayer reported solid results for fiscal 2020 with revenue and core EPS being more or less stable compared to fiscal 2019. A few weeks ago, Bayer also settled the glyphosate litigations.

Bayer: Enough With The Bad News

Danone SA

Charles de Vaulx ( Trades , Portfolio ), chief investment officer of International Value Advisors, has revealed the IVA Worldwide Fund portfolio for the fourth quarter of 2020. Top trades include new buys into Danone SA (XPAR:BN) and Bayer AG (XTER:BAYN) and reductions in Bollore SA (XPAR:BOL) and H U Group Holdings Inc. (TSE:4544).

Charles de Vaulx's Top 4th-Quarter Trades

Bayer AG (BAYZF) CEO Werner Baumann on Q4 2020 Results - Earnings Call Transcript

Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.

Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss

DALLAS, Feb. 24, 2021 /PRNewswire/ -- Bayer, the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement with cancer victims would end its massive legal exposure to pending claims over the herbicide. However, efforts by Bayer (OTC: BAYRY) to resolve...

Bayer's Exposure to Thousands of Cancer Lawsuits Persists as Victims' Lawyers Vow to Continue the Fight

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that new NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place from February 11-13, 2021. Among featured presentations are additional Phase III ARAMIS trial analyses evaluating the crossover effect from placebo to NUBEQA and safety follow-up in men with non-metastatic castration-resistant prostate cancer (

Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and Orion Corporation are expanding the global clinical development program for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in prostate cancer. A new Phase III study ARANOTE will investigate NUBEQA in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). The study builds on the robust development program comprising multiple studies, including the Phase

Bayer and Orion Expand Development Program for NUBEQA® (darolutamide) in Prostate Cancer

Bayer AG struck a $2 billion deal to resolve future legal claims that its widely used weedkiller Roundup causes cancer, the German company said on Wednesday.

Bayer reaches $2 billion deal over future Roundup cancer claims

News for Bayer AG Stock (BAYRY)